Ulcerative Colitis

CTAF

ICER will assess the comparative clinical effectiveness and value of therapies for ulcerative colitis (UC), including:

  • Vedolizumab (Entyvio®, Takeda), subcutaneous and IV formulations
  • Infliximab (Remicade®, Janssen)
  • Infliximab-dyyb (Inflectra®, Pfizer)
  • Infliximab-abda (Renflexis®, Merck)
  • Adalimumab (Humira®, AbbVie)
  • Golimumab (Simponi®, Janssen)
  • Tofacitinib (Xeljanz®, Pfizer)
  • Ustekinumab (Stelara®, Janssen)

Date of Review: June 2020

For questions, please contact Laura Cianciolo, Program Manager, at lcianciolo@icer-review.org.

Associated Meetings

June 30, 2020 10am-4pm PT
California Endowment
2000 Franklin St 4th Floor
Oakland, CA 94612

The CTAF will convene to deliberate and vote on evidence presented in ICER's report on ulcerative colitis therapies.


Key Dates

Associated Materials

09/06/2019 – 09/24/2019
Open Input Period

09/27/2019

09/27/2019 – 10/18/2019

09/27/2019

11/04/2019

12/11/2019
Research Protocol

02/03/2020
Model Analysis Plan

04/01/2020
Draft Evidence Report

04/01/2020
Draft Voting Questions

04/01/2020 – 05/05/2020
Public Comments

06/02/2020
Revised Voting Questions

06/02/2020
Response to Public Comments

06/02/2020
Meeting Agenda

06/02/2020
Evidence Report

06/30/2020
Evidence Presentation

07/17/2020
Final Evidence Report and Meeting Summary

07/17/2020
Report-at-a-Glance